RADIOLABELED LIGANDS FOR CANCER IMAGING

RADIOLABELED LIGANDS FOR CANCER IMAGING

In parallel to our small molecule drug conjugates (SMDCs) program, Philochem has developed and patented a number of radiolabeled ligands for cancer imaging. These radiolabelled ligands consist of a high affinity binder of tumor-associated antigens, conjugated to different chelating moieties for the functionalization with several radioisotopes. PHC-102, a proprietary 99mTc-radiolabelled ligand of Carbonic Anhydrase IX (CAIX, a validated marker of solid tumors), will soon enter in Phase I clinical trial for the imaging of clear cell renal cell carcinoma and hypoxia.

SELECTED REFERENCES

Krall et al. (2016) J. Nucl. Med. 57:943-9;
Cazzamalli et al.(2016) Mol Cancer Ther. [Epub ahead of print];
Minn et al. (2016) Oncotarget. [Epub ahead of print];
Yang et al. (2015) Oncotarget. 6:33733-42

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy
X